A

n axiom in the overheated debate about prescription drug pricing is that Americans are often charged more than what is paid by people in other countries. And internal data from one large drug maker illustrates the point.

In 2014, the most recent year for which data was available, Novartis (NVS) headquarters in Switzerland charged its U.S. subsidiary significantly more for four medicines than what its subsidiaries paid in roughly a dozen other countries. These included several well-to-do nations such as the U.K., Germany, and France. And the difference in pricing ranged anywhere from 45 percent to 176 percent, after adjusting for currency fluctuations and packaging.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Vic N Cancel reply

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.